## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 4.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($83.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251230T130751 | Somewhat-Bullish | Relevance: 100%
- Mirova US LLC has reduced its stake in Edwards Lifesciences Corporation by 3.7%, valuing its remaining 2.8 million shares at approximately $219.47 million, making it their 20th largest holding. Despite recent insider selling, Edwards Lifesciences exceeded quarterly EPS and revenue estimates, prompting analyst upgrades and a "Moderate Buy" consensus rating with a $93.95 price target. The company also provided optimistic FY2025 EPS guidance, signaling strong financial performance moving forward.

**2. Farmers & Merchants Investments Inc. Sells 15,037 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251230T095206 | Somewhat-Bullish | Relevance: 100%
- Farmers & Merchants Investments Inc. reduced its stake in Edwards Lifesciences Corporation by 10.8% in Q3, selling 15,037 shares and retaining 123,745 shares valued at $9.624 million. This comes amidst recent insider selling, with 45,465 shares sold over the past 90 days, bringing insider ownership to about 0.34%. Despite this, analysts maintain a "Moderate Buy" rating with a target price of $93.95, and the company exceeded Q3 EPS and revenue expectations.

**3. U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More**
- Source: Yahoo Finance | 20251229T162823 | Somewhat-Bullish | Relevance: 65%
- The U.S. Embolic Protection Device Market is projected to grow from US$360 million in 2024 to US$650 million by 2033, with a CAGR of 6.96%. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and technological advancements in device design. Key challenges include the high cost of devices and complexities in reimbursement, as well as the need for highly skilled operators to properly use these devices.

**4. UFP Technologies Is Growing Fast, Even If Its Stock Isnâ€™t**
- Source: Finimize | 20251228T210905 | Somewhat-Bullish | Relevance: 61%
- UFP Technologies (UFPT), a specialist in medical device manufacturing, is expanding rapidly due to increased outsourcing demand and strategic acquisitions, yet its stock has underperformed, trading at a discount. Despite strong growth prospects, efficient capital use, and healthy cash flow, UFPT faces risks from customer concentration, regulatory hurdles, and potential margin pressures. The company presents a potentially attractive opportunity for long-term investors interested in medical device outsourcing, despite its recent stock performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.86 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $50.6B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.86 |
| Forward P/E | 30.0 |
| Current P/E | 33.4 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.5% over 5 days). Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.14% (CS: 54) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 1.107x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.21
- **Stop Loss:** $83.19 (3.5% risk)
- **Target:** $89.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 437
- **Position Value:** $37,673.77
- **Portfolio %:** 37.67%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*